Elevated hs-cTnT >14 ng/l was strongly associated with all-cause mortality (HR 12.9; 95% CI 3.5-46.9; p=0.0001) and a composite clinical endpoint in stable ambulatory coronary artery disease patients.
Observational (n=693)
No
Does elevated hs-cTnT (>14 ng/l) predict all-cause mortality and adverse cardiovascular events in stable ambulatory coronary artery disease patients?
Elevated hs-cTnT levels (>14 ng/l) provide strong prognostic information for all-cause mortality and adverse cardiovascular events in stable ambulatory CAD outpatients.
Effect estimate: HR 12.9 (95% CI 3.5-46.9)
p-value: p=0.0001
AIMS: To investigate the prognostic implications of elevated high-sensitivity cardiac troponin T (hs-cTnT) values in presumably stable ambulatory coronary artery disease patients. METHODS AND RESULTS: We conducted a retrospective, single-centre pilot observational study in a low-risk population. All patients received routine measurement of hs-cTnT at index and follow-up visits. Endpoints were all-cause mortality and a composite of all-cause mortality, acute myocardial infarction, stroke and rehospitalization for acute coronary syndrome and heart failure. Nine hundred and sixty-five consecutive patients presenting to our outpatient clinic between June 2009 and June 2010 were screened; 693 patients with a stable clinical course, at least one hs-cTnT value and at least one follow-up visit qualified for analysis. Follow-up was 796 days. Five hundred and forty-seven patients (78.9%) had hs-cTnT values below and 146 patients (21.1%) had values above 14 ng/l, which was defined to categorize high and low levels as it was reported to be the 99th percentile of a reference population. We observed 13 deaths (all-cause mortality) including four cardiovascular deaths. Age, N terminal pro-brain natriuretic peptide levels and impaired renal function were independently associated with an elevated hs-cTnT in a multivariate analysis. Hs-cTnT values >14 ng/l were strongly associated with all-cause mortality (hazard ratio 12.9, 95% confidence interval (CI): 3.5-46.9, p=0.0001), the composite clinical endpoint (hazard ratio 2.35, 95% CI: 1.48-3.72, p=0.0003) and rehospitalization for heart failure (hazard ratio 3.36, 95% CI: 1.73-6.53, p=0.0004). Compared with the multivariable Framingham score hs-cTnT revealed a significantly better performance (area under the receiver operating characteristics curve (AUC) hs-cTnT: 0.882 vs. AUC Framingham score 0.639, p=0.0005). CONCLUSION: Elevated hs-cTnT levels provide excellent prognostic information regarding all-cause mortality and a combined clinical endpoint in presumably stable ambulatory coronary artery disease outpatients presenting for routine evaluation.
قام بينر وآخرون (الجمعة) بإجراء دراسة رصدية في مرضى الشرايين التاجية المستقرة (عدد = 693). تم تقييم hs-cTnT المرتفع (>14 نانوغرام/لتر) مقابل hs-cTnT ≤14 نانوغرام/لتر على معدل الوفيات لجميع الأسباب (HR 12.9، 95% CI 3.5-46.9، p=0.0001). كان hs-cTnT المرتفع >14 نانوغرام/لتر مرتبطًا بشدة بمعدل الوفيات لجميع الأسباب (HR 12.9؛ 95% CI 3.5-46.9؛ p=0.0001) ونقطة نهاية سريرية مركبة في مرضى الشرايين التاجية المستقرة.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: